{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:00:42Z","timestamp":1784782842831,"version":"3.55.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00210-026-05395-6","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:33:55Z","timestamp":1777527235000},"page":"16541-16556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications"],"prefix":"10.1007","volume":"399","author":[{"given":"Abbas S.","family":"Neamah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"5395_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1033705","volume":"13","author":"M Abdeladhim","year":"2022","unstructured":"Abdeladhim M, Karnell JL, Rieder SA (2022) In or out of control: modulating regulatory T cell homeostasis and function with immune checkpoint pathways. Front Immunol 13:1033705","journal-title":"Front Immunol"},{"issue":"22_Supplement","key":"5395_CR2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.TUMBODY-B012","volume":"84","author":"M Abudula","year":"2024","unstructured":"Abudula M, Astuti Y, Raymant MR, Sharma V, Schmid M, Mielgo A (2024) Abstract B012: understanding the role of VISTA in regulating T cell function and the therapeutic potential of blocking VISTA in triple negative breast cancer. Cancer Res 84(22_Supplement):B012-B012","journal-title":"Cancer Res"},{"issue":"1","key":"5395_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08927-x","volume":"22","author":"A Afaya","year":"2022","unstructured":"Afaya A, Ramazanu S, Bolarinwa OA, Yakong VN, Afaya RA, Aboagye RG, Daniels-Donkor SS, Yahaya A-R, Shin J, Dzomeku VM (2022) Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review. BMC Health Serv Res 22(1):1601","journal-title":"BMC Health Serv Res"},{"key":"5395_CR4","doi-asserted-by":"publisher","unstructured":"Agelidis A, Ter-Zakarian A, Jaloudi M (2025) Triple-negative breast cancer on the rise: breakthroughs and beyond. Breast Cancer: Targ Ther 523\u2013529.\u00a0https:\/\/doi.org\/10.2147\/BCTT.S516125","DOI":"10.2147\/BCTT.S516125"},{"issue":"1","key":"5395_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqae012","volume":"5","author":"NF Ahsan","year":"2024","unstructured":"Ahsan NF, Louren\u00e7o S, Psyllou D, Long A, Shankar S, Bashford-Rogers R (2024) The current understanding of the phenotypic and functional properties of human regulatory B cells (Bregs). Oxf Open Immunol 5(1):iqae012","journal-title":"Oxf Open Immunol"},{"issue":"9","key":"5395_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s12032-025-02955-3","volume":"42","author":"OQB Allela","year":"2025","unstructured":"Allela OQB, Shareef A, Vadia N, Oweis R, Jyothi SR, Maharana L, Chauhan AS, Tomar P, Sameer HN, Yaseen A (2025) TIGIT, as a potential immune checkpoint target for immunotherapy of breast cancer. Med Oncol 42(9):407","journal-title":"Med Oncol"},{"issue":"5","key":"5395_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050880","volume":"17","author":"S Almawash","year":"2025","unstructured":"Almawash S (2025) Revolutionary cancer therapy for personalization and improved efficacy: strategies to overcome resistance to immune checkpoint inhibitor therapy. Cancers 17(5):880","journal-title":"Cancers"},{"issue":"8","key":"5395_CR8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.32604\/or.2025.065953","volume":"33","author":"E Alvarado-Ortiz","year":"2025","unstructured":"Alvarado-Ortiz E, Sarabia-S\u00e1NCHEZ MA (2025) Hypoxic link between cancer cells and the immune system: the role of adenosine and lactate. Oncol Res 33(8):1803","journal-title":"Oncol Res"},{"key":"5395_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"key":"5395_CR10","doi-asserted-by":"crossref","unstructured":"Arzanova E, Mayrovitz HN (2022) The epidemiology of breast cancer. Exon Publ: 1\u201319","DOI":"10.36255\/exon-publications-breast-cancer-epidemiology"},{"issue":"1","key":"5395_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02476-1","volume":"41","author":"K Asleh","year":"2022","unstructured":"Asleh K, Riaz N, Nielsen TO (2022) Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res 41(1):265","journal-title":"J Exp Clin Cancer Res"},{"key":"5395_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1421346","volume":"15","author":"F Bahman","year":"2024","unstructured":"Bahman F, Choudhry K, Al-Rashed F, Al-Mulla F, Sindhu S, Ahmad R (2024) Aryl hydrocarbon receptor: current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases. Front Immunol 15:1421346","journal-title":"Front Immunol"},{"issue":"1","key":"5395_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/imr.13230","volume":"320","author":"ZJ Bernstein","year":"2023","unstructured":"Bernstein ZJ, Shenoy A, Chen A, Heller NM, Spangler JB (2023) Engineering the IL-4\/IL-13 axis for targeted immune modulation. Immunol Rev 320(1):29\u201357","journal-title":"Immunol Rev"},{"key":"5395_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101654","author":"M Bruchard","year":"2022","unstructured":"Bruchard M, Spits H (2022) The role of ILC subsets in cancer. Semin Immunol. https:\/\/doi.org\/10.1016\/j.smim.2022.101654","journal-title":"Semin Immunol"},{"key":"5395_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795","volume":"12","author":"D Catal\u00e1n","year":"2021","unstructured":"Catal\u00e1n D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguill\u00f3n JC, Aravena O (2021) Immunosuppressive mechanisms of regulatory B cells. Front Immunol 12:611795","journal-title":"Front Immunol"},{"issue":"1","key":"5395_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-immunol-101921-045939","volume":"41","author":"W Chen","year":"2023","unstructured":"Chen W (2023) TGF-\u03b2 regulation of T cells. Annu Rev Immunol 41(1):483\u2013512","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"5395_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01000-5","volume":"15","author":"B Chen","year":"2024","unstructured":"Chen B, Liu Y, He Y, Shen C (2024a) Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation. Discov Oncol 15(1):139","journal-title":"Discov Oncol"},{"issue":"1","key":"5395_CR18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12967-024-05134-6","volume":"22","author":"Y Chen","year":"2024","unstructured":"Chen Y, Yu D, Qian H, Shi Y, Tao Z (2024b) CD8+ T cell-based cancer immunotherapy. J Transl Med 22(1):394","journal-title":"J Transl Med"},{"key":"5395_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1684889","volume":"16","author":"K Chen","year":"2025","unstructured":"Chen K, Luo L, Li Y, Yang G (2025) Reprogramming the immune microenvironment in lung cancer. Front Immunol 16:1684889","journal-title":"Front Immunol"},{"issue":"8","key":"5395_CR20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA (2022) The complex role of tumor-infiltrating macrophages. Nat Immunol 23(8):1148\u20131156","journal-title":"Nat Immunol"},{"issue":"1","key":"5395_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R (2023) Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer 22(1):93","journal-title":"Mol Cancer"},{"issue":"1","key":"5395_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/imr.13092","volume":"311","author":"DN Clark","year":"2022","unstructured":"Clark DN, Begg LR, Filiano AJ (2022) Unique aspects of IFN\u2010\u03b3\/STAT1 signaling in neurons. Immunol Rev 311(1):187\u2013204","journal-title":"Immunol Rev"},{"issue":"2","key":"5395_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, Besse B (2022) Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol 19(2):75\u201390","journal-title":"Nat Rev Clin Oncol"},{"key":"5395_CR24","volume":"63","author":"MO Fj\u00f8rtoft","year":"2024","unstructured":"Fj\u00f8rtoft MO, Huse K, Rye IH (2024) The tumor immune microenvironment in breast cancer progression. Acta Oncol 63:33008","journal-title":"Acta Oncol"},{"issue":"23","key":"5395_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312848","volume":"25","author":"O Franzese","year":"2024","unstructured":"Franzese O (2024) Tumor microenvironment drives the cross-talk between co-stimulatory and inhibitory molecules in tumor-infiltrating lymphocytes: implications for optimizing immunotherapy outcomes. Int J Mol Sci 25(23):12848","journal-title":"Int J Mol Sci"},{"key":"5395_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1359914","volume":"15","author":"Q Gan","year":"2024","unstructured":"Gan Q, Li Y, Li Y, Liu H, Chen D, Liu L, Peng C (2024) Pathways and molecules for overcoming immunotolerance in metastatic gastrointestinal tumors. Front Immunol 15:1359914","journal-title":"Front Immunol"},{"issue":"22","key":"5395_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17223627","volume":"17","author":"NT Garc\u00eda-Barrientos","year":"2025","unstructured":"Garc\u00eda-Barrientos NT, Solorzano-Ibarra F, Klimov-Kravtchenko K, Rojas-Diaz JM, Guitron-Avi\u00f1a MS, Ceja-Flores FJ, Cruz-Ramos JA, Ortiz-Lazareno PC, Bustos-Rodriguez FdJ, Vazquez-Limon JC (2025) T cell exhaustion in the cervical cancer tumor microenvironment: PD-1 overexpression and co-expression with TIGIT, Tim-3, LAG-3, and NKG2A. Cancers 17(22):3627","journal-title":"Cancers"},{"issue":"10","key":"5395_CR28","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/art.43210","volume":"77","author":"S Giryes","year":"2025","unstructured":"Giryes S, Wong C, Bridgewood C, Harland M, Altaie A, McDermott N, Abacar K, Rao A, Khan A, McMillan T (2025) Paradoxical activation of entheseal myeloid cells by JAK1 and Tyk2 inhibitors via interleukin\u201010 antagonism. Arthritis & rheumatology (Hoboken, NJ) 77(10):1373","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"key":"5395_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1440269","volume":"15","author":"Y Grobben","year":"2024","unstructured":"Grobben Y (2024) Targeting amino acid-metabolizing enzymes for cancer immunotherapy. Front Immunol 15:1440269","journal-title":"Front Immunol"},{"issue":"1","key":"5395_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s13105-023-00989-7","volume":"80","author":"Q Gu","year":"2024","unstructured":"Gu Q, Xiao Y-B, Wang Y (2024) Silencing suppressor of cytokine signaling 3 induces apoptosis and activates the p-STAT3\/NF-\u03baB pathway in hypoxic cultivated H9c2 cells. J Physiol Biochem 80(1):127\u2013136","journal-title":"J Physiol Biochem"},{"issue":"4","key":"5395_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041130","volume":"15","author":"L Guidi","year":"2023","unstructured":"Guidi L, Pellizzari G, Tarantino P, Valenza C, Curigliano G (2023) Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges. Cancers 15(4):1130","journal-title":"Cancers"},{"issue":"2","key":"5395_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12282-024-01654-7","volume":"32","author":"R Guo","year":"2025","unstructured":"Guo R, Wang P (2025) The complex role of regulatory cells in breast cancer: implication for immunopathogenesis and immunotherapy. Breast Cancer 32(2):227\u2013241","journal-title":"Breast Cancer"},{"issue":"1","key":"5395_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/imm.70035","volume":"177","author":"MJ Hayati","year":"2026","unstructured":"Hayati MJ, Yaghmoorian Khojini J, Khara F, Heydari A, Vousooghi N, Abootorabi SMS, Barkhordar M, Mousavi MJ (2026) Gamma delta T cells in the tumour microenvironment: a double-edged sword. Immunology 177(1):44\u201358","journal-title":"Immunology"},{"issue":"1","key":"5395_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C (2025) Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer 24(1):5","journal-title":"Mol Cancer"},{"issue":"8_Supplement_2","key":"5395_CR35","doi-asserted-by":"publisher","first-page":"CT074","DOI":"10.1158\/1538-7445.AM2025-CT074","volume":"85","author":"D Hess","year":"2025","unstructured":"Hess D, Mach N, Jamal R, Stathis A, Powell SF, Joerger M, Loboda A, Chen Y, Shumway S, Knelson EH (2025) Abstract CT074: Discovery and preliminary clinical findings of MK-6598, a potent and selective inhibitor of the immune checkpoint IL4I1. Cancer Res 85(8_Supplement_2):CT074\u2013CT074","journal-title":"Cancer Res"},{"key":"5395_CR36","unstructured":"Howard AE (2022) Transgenerational effects of trauma through epigenetic mechanisms, Azusa Pacific University"},{"issue":"1","key":"5395_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu Y, Hu Q, Li Y, Lu L, Xiang Z, Yin Z, Kabelitz D, Wu Y (2023) \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct Target Ther 8(1):434","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5395_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","volume":"9","author":"A Hu","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y (2024) Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Ther 9(1):68","journal-title":"Signal Transduct Target Ther"},{"key":"5395_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226443","volume":"14","author":"J Huang","year":"2023","unstructured":"Huang J, Zhao Y, Zhao K, Yin K, Wang S (2023a) Function of reactive oxygen species in myeloid-derived suppressor cells. Front Immunol 14:1226443","journal-title":"Front Immunol"},{"key":"5395_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1263537","volume":"14","author":"P Huang","year":"2023","unstructured":"Huang P, Zhou X, Zheng M, Yu Y, Jin G, Zhang S (2023b) Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer. Front Immunol 14:1263537","journal-title":"Front Immunol"},{"issue":"1","key":"5395_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01455-z","volume":"22","author":"M Huang","year":"2024","unstructured":"Huang M, Yu X, Wang Q, Jiang Z, Li X, Chen W, Song C (2024) The immune checkpoint TIGIT\/CD155 promotes the exhaustion of CD8+ T cells in TNBC through glucose metabolic reprogramming mediated by PI3K\/AKT\/mTOR signaling. Cell Commun Signal 22(1):35","journal-title":"Cell Commun Signal"},{"key":"5395_CR42","unstructured":"Ito A (n.d.) Possible metastatic stage-dependent ILC2 activation induces differential functions of MDSCs through IL-13\/IL-13R1 signaling during the progression of breast cancer lung metastasis"},{"issue":"3","key":"5395_CR43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41590-022-01127-z","volume":"23","author":"N Jacquelot","year":"2022","unstructured":"Jacquelot N, Seillet C, Vivier E, Belz GT (2022) Innate lymphoid cells and cancer. Nat Immunol 23(3):371\u2013379","journal-title":"Nat Immunol"},{"key":"5395_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303605","volume":"14","author":"H Jia","year":"2023","unstructured":"Jia H, Yang H, Xiong H, Luo KQ (2023) NK cell exhaustion in the tumor microenvironment. Front Immunol 14:1303605","journal-title":"Front Immunol"},{"issue":"1","key":"5395_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","volume":"6","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, Zhang H, Gao Y, Sun Y (2025) Multi-omics strategies for biomarker discovery and application in personalized oncology. Mol Biomed 6(1):115","journal-title":"Mol Biomed"},{"issue":"11","key":"5395_CR46","doi-asserted-by":"publisher","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","volume":"50","author":"R Kaur","year":"2023","unstructured":"Kaur R, Bhardwaj A, Gupta S (2023) Cancer treatment therapies: Traditional to modern approaches to combat cancers. Mol Biol Rep 50(11):9663\u20139676","journal-title":"Mol Biol Rep"},{"issue":"7","key":"5395_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/CJI.0000000000000368","volume":"44","author":"N Kotecki","year":"2021","unstructured":"Kotecki N, Vuagnat P, O\u2019Neil BH, Jalal S, Rottey S, Prenen H, Benhadji KA, Xia M, Szpurka AM, Saha A (2021) A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer. J Immunother 44(7):264\u2013275","journal-title":"J Immunother"},{"key":"5395_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638102","volume":"16","author":"OV Kovaleva","year":"2025","unstructured":"Kovaleva OV, Rashidova MA, Sinyov VV, Malashenko OS, Gratchev A (2025) M1 macrophages\u2013unexpected contribution to tumor progression. Front Immunol 16:1638102","journal-title":"Front Immunol"},{"issue":"8","key":"5395_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12032-025-02906-y","volume":"42","author":"N Krakhmal","year":"2025","unstructured":"Krakhmal N, Taranenko M, Naumov S, Vtorushin S (2025) From heterogeneity to hope: Emerging markers in triple-negative breast cancer research. Med Oncol 42(8):337","journal-title":"Med Oncol"},{"issue":"2","key":"5395_CR50","first-page":"187","volume":"74","author":"G Kroemer","year":"2024","unstructured":"Kroemer G, Chan TA, Eggermont AM, Galluzzi L (2024) Immunosurveillance in clinical cancer management. CA Cancer J Clin 74(2):187\u2013202","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5395_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont CM, Nelson BH (2023) B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41(3):466\u2013489","journal-title":"Cancer Cell"},{"issue":"7","key":"5395_CR52","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","volume":"22","author":"CM Laumont","year":"2022","unstructured":"Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH (2022) Tumour-infiltrating B cells: Immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer 22(7):414\u2013430","journal-title":"Nat Rev Cancer"},{"key":"5395_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256769","volume":"13","author":"RA Leon-Letelier","year":"2023","unstructured":"Leon-Letelier RA, Dou R, Vykoukal J, Sater AHA, Ostrin E, Hanash S, Fahrmann JF (2023) The kynurenine pathway presents multi-faceted metabolic vulnerabilities in cancer. Front Oncol 13:1256769","journal-title":"Front Oncol"},{"key":"5395_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1083462","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, Liu S (2022) Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer. Front Immunol 13:1083462","journal-title":"Front Immunol"},{"issue":"5","key":"5395_CR55","volume":"8","author":"R Li","year":"2025","unstructured":"Li R, Lv W, Wang DL, Chen N (2025a) A systematic review of immune cell roles in breast cancer immunotherapy. Cancer Rep 8(5):e70217","journal-title":"Cancer Rep"},{"key":"5395_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1640073","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Meng H, Wang H, Zhang Y, Yu W (2025b) Indoleamine 2, 3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation. Front Pharmacol 16:1640073","journal-title":"Front Pharmacol"},{"issue":"1","key":"5395_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23(1):108","journal-title":"Mol Cancer"},{"issue":"7","key":"5395_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70403","volume":"15","author":"P Lin","year":"2025","unstructured":"Lin P, Lin Y, Chen X, Zhao X, Cui L (2025) Decoding MHC loss: molecular mechanisms and implications for immune resistance in cancer. Clin Transl Med 15(7):e70403","journal-title":"Clin Transl Med"},{"issue":"1","key":"5395_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X (2023a) Advances in immunotherapy for triple-negative breast cancer. Mol Cancer 22(1):145","journal-title":"Mol Cancer"},{"issue":"7","key":"5395_CR60","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41416-023-02321-y","volume":"129","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu Z, Yang Y, Cui J, Sun J, Liu Y (2023b) The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. Br J Cancer 129(7):1041\u20131049","journal-title":"Br J Cancer"},{"issue":"1","key":"5395_CR61","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12967-024-05327-z","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Wu M, Yang Y, Wang Z, He S, Tian X, Wang H (2024) \u03b3\u03b4 T cells and the PD-1\/PD-L1 axis: a love\u2013hate relationship in the tumor microenvironment. J Transl Med 22(1):553","journal-title":"J Transl Med"},{"issue":"3","key":"5395_CR62","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.104079","volume":"21","author":"Q Liu","year":"2025","unstructured":"Liu Q, Liu Z, Zhang X, Zeng A, Song L (2025a) Revisiting of cancer immunotherapy: insight from the dialogue between glycolysis and PD-1\/PD-L1 axis in the tumor microenvironment. Int J Biol Sci 21(3):1202","journal-title":"Int J Biol Sci"},{"key":"5395_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1499663","volume":"16","author":"R Liu","year":"2025","unstructured":"Liu R, Jiang X, Dong R, Zhang Y, Gai C, Wei P (2025b) Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families. Front Immunol 16:1499663","journal-title":"Front Immunol"},{"issue":"03","key":"5395_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cpt.2024.07.004","volume":"3","author":"R Liu","year":"2025","unstructured":"Liu R, Li J, Liu L, Wang W, Jia J (2025c) Tumor-associated macrophages (TAMs): constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC)\u2606. Cancer Pathog Ther 3(03):183\u2013196","journal-title":"Cancer Pathog Ther"},{"issue":"1","key":"5395_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s43556-026-00403-w","volume":"7","author":"J Liu","year":"2026","unstructured":"Liu J, Wang Y, Tang C, Zhang L, Xiong S, Wang J, Dong C (2026) TGF-\u03b2 in tumor development and progression: mechanisms and therapeutics. Mol Biomed 7(1):9","journal-title":"Mol Biomed"},{"issue":"1","key":"5395_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, Zhang B, Li Y, Liu B, Xia L (2024) Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol 13(1):39","journal-title":"Exp Hematol Oncol"},{"key":"5395_CR67","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A (2021) Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review. Cancers 13(17):4287","DOI":"10.3390\/cancers13174287"},{"issue":"6","key":"5395_CR68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41416-021-01674-6","volume":"126","author":"A Lundberg","year":"2022","unstructured":"Lundberg A, Li B, Li R (2022) B cell-related gene signature and cancer immunotherapy response. Br J Cancer 126(6):899\u2013906","journal-title":"Br J Cancer"},{"issue":"4","key":"5395_CR69","volume":"73","author":"N Mansuri","year":"2025","unstructured":"Mansuri N, Asma\u2019a HM, Ahsan M, Ali SA-J, Qureshi MA, Aldhaaban WA, Mallick AK, Mohammed MED, Ahmad F, Ahmad I (2025) The immunobiological functions and therapeutic applications of interleukin-17 family in cancer. Curr Res Transl Med 73(4):103527","journal-title":"Curr Res Transl Med"},{"issue":"9","key":"5395_CR70","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cancers17091408","volume":"17","author":"V Mc Neil","year":"2025","unstructured":"Mc Neil V, Lee SW (2025) Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies. Cancers Basel 17(9):1408","journal-title":"Cancers Basel"},{"issue":"5","key":"5395_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051360","volume":"14","author":"V Men\u00e9ndez","year":"2022","unstructured":"Men\u00e9ndez V, Sol\u00f3rzano JL, Fern\u00e1ndez S, Montalb\u00e1n C, Garc\u00eda JF (2022) The Hodgkin lymphoma immune microenvironment: turning bad news into good. Cancers Basel 14(5):1360","journal-title":"Cancers Basel"},{"key":"5395_CR72","doi-asserted-by":"publisher","unstructured":"Meyaard L, van der Vlist M (2026) Targeting inhibitory immune receptors in inflammatory disease, guided by molecular understanding of their function. Ann Rev Immunol\u00a044.\u00a0https:\/\/doi.org\/10.1146\/annurev-immunol-083024-025659","DOI":"10.1146\/annurev-immunol-083024-025659"},{"key":"5395_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.981847","volume":"13","author":"H Moreira","year":"2022","unstructured":"Moreira H, Dobosz A, Cwynar-Zaj\u0105c \u0141, Nowak P, Czy\u017cewski M, Barg M, Reichert P, Kr\u00f3likowska A, Barg E (2022) Unraveling the role of Breg cells in digestive tract cancer and infectious immunity. Front Immunol 13:981847","journal-title":"Front Immunol"},{"key":"5395_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121083","volume":"310","author":"K Mortezaee","year":"2022","unstructured":"Mortezaee K, Majidpoor J, Najafi S (2022) VISTA immune regulatory effects in bypassing cancer immunotherapy: updated. Life Sci 310:121083","journal-title":"Life Sci"},{"key":"5395_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1629401","volume":"13","author":"P Nathani","year":"2025","unstructured":"Nathani P, Tailor P, Bhandarkar P, Patil P, Pimpalkar P, Swaminathan N, Sawhney R, Roy N, Gadgil A (2025) Ten-year survival in early-stage breast cancer patients in a comprehensive breast cancer care program in India. Front Public Health 13:1629401","journal-title":"Front Public Health"},{"key":"5395_CR76","doi-asserted-by":"crossref","unstructured":"Neamah AS, Lafta FM (2024) Diagnostic potential role of CXCL3 and leptin levels in breast cancer. Iraqi J Sci 65(4):1929\u20131939","DOI":"10.24996\/ijs.2024.65.4.13"},{"key":"5395_CR77","doi-asserted-by":"crossref","unstructured":"Neamah AS, Lafta FM, Wadan AHS (2025) Targeting mitochondrial metabolism to overcome hormone resistance in breast cancer. Naunyn-Schmiedeberg\u2019s Arch Pharmacol :1\u201317","DOI":"10.1007\/s00210-025-04487-z"},{"issue":"4","key":"5395_CR78","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1007\/s00210-024-03592-9","volume":"398","author":"AS Neamah","year":"2025","unstructured":"Neamah AS, Wadan A-H, Lafta FM, Elakwa D-S (2025b) The potential role of targeting the leptin receptor as a treatment for breast cancer in the context of hyperleptinemia: a literature review. Naunyn-Schmiedebergs Arch Pharmacol 398(4):3451\u20133466","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"5395_CR79","unstructured":"Ngomti A (2022) The role of interleukin-4 induced gene 1 (IL-4i1) in allergic asthma and atopic dermatitis"},{"issue":"7","key":"5395_CR80","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/cells14070488","volume":"14","author":"A Nishida","year":"2025","unstructured":"Nishida A, Andoh A (2025) The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis. Cells 14(7):488","journal-title":"Cells"},{"issue":"5","key":"5395_CR81","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/08830185.2025.2490233","volume":"44","author":"W Nouari","year":"2025","unstructured":"Nouari W, Aribi M (2025) Innate lymphoid cells, immune functional dynamics, epithelial parallels, and therapeutic frontiers in infections. Int Rev Immunol 44(5):245\u2013272","journal-title":"Int Rev Immunol"},{"issue":"11","key":"5395_CR82","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41573-022-00538-9","volume":"21","author":"R Offringa","year":"2022","unstructured":"Offringa R, K\u00f6tzner L, Huck B, Urbahns K (2022) The expanding role for small molecules in immuno-oncology. Nat Rev Drug Discov 21(11):821\u2013840","journal-title":"Nat Rev Drug Discov"},{"key":"5395_CR83","doi-asserted-by":"crossref","unstructured":"Oisakede EO, Akinro O, Bello OJ, Analikwu CC, Egbon E, Olawade DB (2025) Predictive models for checkpoint inhibitor response in cancer: a review of current approaches and future directions. Crit Rev Oncol\/hematol 104980","DOI":"10.1016\/j.critrevonc.2025.104980"},{"key":"5395_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fsens.2022.789771","volume":"3","author":"N Pandey","year":"2022","unstructured":"Pandey N, Biswas D, Dutta N, Hansda A, Dutta G, Mukherjee G (2022) Sensing soluble immune checkpoint molecules and disease-relevant cytokines in cancer: a novel paradigm in disease diagnosis and monitoring. Front Sens 3:789771","journal-title":"Front Sens"},{"key":"5395_CR85","unstructured":"Pontis F (2025) Role of plasma extracellular vesicles in lung cancer pre-metastatic niche formation. The Open University"},{"issue":"22","key":"5395_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225493","volume":"15","author":"Q Pu","year":"2023","unstructured":"Pu Q, Gao H (2023) The role of the tumor microenvironment in triple-positive breast cancer progression and therapeutic resistance. Cancers Basel 15(22):5493","journal-title":"Cancers Basel"},{"issue":"1","key":"5395_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-02096-y","volume":"10","author":"M Qin","year":"2024","unstructured":"Qin M, Fang Y, Zheng Q, Peng M, Wang L, Sang X, Cao G (2024) Tissue microenvironment induces tissue specificity of ILC2. Cell Death Discov 10(1):324","journal-title":"Cell Death Discov"},{"key":"5395_CR88","doi-asserted-by":"crossref","unstructured":"Radosavljevic GD, Pantic J, Markovic BS, Arsenijevic N (2022) Modulators of tumor angiogenesis: insights into the role of galectin-3 and IL-17 signaling. tumor angiogenesis and modulators, intechopen","DOI":"10.5772\/intechopen.102893"},{"key":"5395_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1154631","volume":"13","author":"I Rezouki","year":"2023","unstructured":"Rezouki I, Zohair B, Ssi SA, Karkouri M, Razzouki I, Elkarroumi M, Badou A (2023) High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. Front Oncol 13:1154631","journal-title":"Front Oncol"},{"key":"5395_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105148","author":"R Roy","year":"2026","unstructured":"Roy R, Haldar A, Das PK, Biswas N (2026) Post-treatment tumor immune microenvironment and the dual role of myeloid-derived suppressor cells (MDSCs) in cancer progression and therapeutic resistance. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105148","journal-title":"Crit Rev Oncol Hematol"},{"key":"5395_CR91","doi-asserted-by":"crossref","unstructured":"Sadeghi M, Dehnavi S, Sharifat M, Amiri AM, Khodadadi\u00a0A (2024) Innate immune cells: key players of orchestra in modulating tumor microenvironment (TME). Heliyon 10(5)","DOI":"10.1016\/j.heliyon.2024.e27480"},{"issue":"4","key":"5395_CR92","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cpt.2023.11.001","volume":"2","author":"P Sarangi","year":"2024","unstructured":"Sarangi P (2024) Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer. Cancer Pathog Ther 2(4):246\u2013255","journal-title":"Cancer Pathog Ther"},{"issue":"16","key":"5395_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163996","volume":"14","author":"I Schlam","year":"2022","unstructured":"Schlam I, Tarantino P, Tolaney SM (2022) Overcoming resistance to HER2-directed therapies in breast cancer. Cancers Basel 14(16):3996","journal-title":"Cancers Basel"},{"issue":"17","key":"5395_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713469","volume":"24","author":"JP Sikora","year":"2023","unstructured":"Sikora JP, Karawani J, Sobczak J (2023) Neutrophils and the systemic inflammatory response syndrome (SIRS). Int J Mol Sci 24(17):13469","journal-title":"Int J Mol Sci"},{"key":"5395_CR95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.32948\/ajsep.2024.11.18","volume":"1","author":"J Smith","year":"2024","unstructured":"Smith J (2024) Role of PD-1\/PD-L1 crosstalk on inhibition of T-cell activation and proliferation through blockade of PI3K\/Akt\/mTOR signaling pathway. Asia Pac J Surg Exp Pathol 1:49\u201356","journal-title":"Asia Pac J Surg Exp Pathol"},{"key":"5395_CR96","volume":"7","author":"P Spiliopoulou","year":"2024","unstructured":"Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M (2024) Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resist 7:2","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"5395_CR97","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.3390\/cancers15112895","volume":"15","author":"TW Stone","year":"2023","unstructured":"Stone TW, Williams RO (2023a) Interactions of IDO and the kynurenine pathway with cell transduction systems and metabolism at the inflammation\u2013cancer interface. Cancers 15(11):2895","journal-title":"Cancers"},{"issue":"7","key":"5395_CR98","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2023.04.006","volume":"44","author":"TW Stone","year":"2023","unstructured":"Stone TW, Williams RO (2023b) Modulation of T cells by tryptophan metabolites in the kynurenine pathway. Trends Pharmacol Sci 44(7):442\u2013456","journal-title":"Trends Pharmacol Sci"},{"issue":"21","key":"5395_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215456","volume":"14","author":"X Sun","year":"2022","unstructured":"Sun X, Liu K, Lu S, He W, Du Z (2022) Targeted therapy and immunotherapy for heterogeneous breast cancer. Cancers 14(21):5456","journal-title":"Cancers"},{"key":"5395_CR100","doi-asserted-by":"crossref","unstructured":"Tahmasebi S, Alimohammadi M, Khorasani S, Rezaei N (2025) Pro-tumorigenic and anti-tumorigenic roles of pro-inflammatory cytokines in cancer. Cancer immunology: the immune system and tumor. Springer 529\u2013553","DOI":"10.1007\/978-3-032-00749-0_25"},{"key":"5395_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.876451","volume":"12","author":"K Tan","year":"2022","unstructured":"Tan K, Naylor MJ (2022) Tumour microenvironment-immune cell interactions influencing breast cancer heterogeneity and disease progression. Front Oncol 12:876451","journal-title":"Front Oncol"},{"issue":"1","key":"5395_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang C-H, Li N (2025) Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther 10(1):227","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5395_CR103","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2363000","volume":"13","author":"S Tumbath","year":"2024","unstructured":"Tumbath S, Jiang L, Li X, Zhang T, Zahid KR, Zhao Y, Zhou H, Yin Z, Lu T, Jiang S (2024) \u03b2-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers. Oncoimmunology 13(1):2363000","journal-title":"Oncoimmunology"},{"issue":"4","key":"5395_CR104","doi-asserted-by":"publisher","first-page":"146","DOI":"10.33696\/immunology.7.235","volume":"7","author":"I Voloshyna","year":"2025","unstructured":"Voloshyna I, Tyagi A, Idga S, Wang N, Amin T, Hanna M, Mukhtar A, Torres F, Kabir F, Florian D (2025) Mechanisms and therapeutic strategies to overcome immune checkpoint inhibitor resistance in melanoma, head and neck, and triple-negative breast cancers. J Cell Immunol 7(4):146\u2013172","journal-title":"J Cell Immunol"},{"key":"5395_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106359","author":"X Wang","year":"2023","unstructured":"Wang X, Fan D, Yang Y, Gimple RC, Zhou S (2023) Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities. iScience. https:\/\/doi.org\/10.1016\/j.isci.2023.106359","journal-title":"iScience"},{"issue":"22","key":"5395_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212223","volume":"25","author":"J Wang","year":"2024","unstructured":"Wang J, He Y, Hu F, Hu C, Sun Y, Yang K, Yang S (2024) Metabolic reprogramming of immune cells in the tumor microenvironment. Int J Mol Sci 25(22):12223","journal-title":"Int J Mol Sci"},{"key":"5395_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1040163","volume":"13","author":"Y Wen","year":"2022","unstructured":"Wen Y, Zhu Y, Zhang C, Yang X, Gao Y, Li M, Yang H, Liu T, Tang H (2022) Chronic inflammation, cancer development and immunotherapy. Front Pharmacol 13:1040163","journal-title":"Front Pharmacol"},{"issue":"2","key":"5395_CR108","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH (2023) Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol 23(2):90\u2013105","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5395_CR109","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, Bu T, Xiao Q, Ding K (2025) Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct Target Ther 10(1):268","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5395_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07370-w","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wang W (2025) Recent progress in immune evasion mechanisms of triple-negative breast cancer. J Transl Med 23(1):1314","journal-title":"J Transl Med"},{"issue":"1","key":"5395_CR111","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K (2022) Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer 21(1):28","journal-title":"Mol Cancer"},{"issue":"9","key":"5395_CR112","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh D-Y (2024) HER2-targeted therapies beyond breast cancer\u2014an update. Nat Rev Clin Oncol 21(9):675\u2013700","journal-title":"Nat Rev Clin Oncol"},{"key":"5395_CR113","unstructured":"Zeitler LK (2023) Mechanisms of cell regulation by the immunosuppressive L-amino acid oxidase IL4i1, Technische Universit\u00e4t M\u00fcnchen"},{"key":"5395_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961374","volume":"12","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhang J, Liu N, Wang B, Zhou Y, Yang J (2022) VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC. Front Oncol 12:961374","journal-title":"Front Oncol"},{"issue":"1","key":"5395_CR115","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13062-023-00401-w","volume":"18","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ma S, Li T, Tian Y, Zhou H, Wang H, Huang L (2023a) ILC1-derived IFN-\u03b3 regulates macrophage activation in colon cancer. Biol Direct 18(1):56","journal-title":"Biol Direct"},{"issue":"3","key":"5395_CR116","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/cancers15030682","volume":"15","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yao Q, Pan Y, Fang X, Xu H, Zhao T, Zhu G, Jiang T, Li S, Cao H (2023b) Efficacy and safety of PD-1\/PD-L1 checkpoint inhibitors versus anti-PD-1\/PD-L1 combined with other therapies for tumors: a systematic review. Cancers Basel 15(3):682","journal-title":"Cancers Basel"},{"issue":"12","key":"5395_CR117","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.7150\/thno.111096","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang J, Miao C, Zhang H (2025a) Targeting neutrophil extracellular traps in cancer progression and metastasis. Theranostics 15(12):5846\u20135869","journal-title":"Theranostics"},{"issue":"3","key":"5395_CR118","first-page":"287","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ji Y, Liu S, Li J, Wu J, Jin Q, Liu X, Duan H, Feng Z, Liu Y (2025b) Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN. J Natl Cancer Cent 5(3):287","journal-title":"J Natl Cancer Cent"},{"issue":"5","key":"5395_CR119","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.3390\/ijms24054285","volume":"24","author":"C Zhao","year":"2023","unstructured":"Zhao C, Guo H, Hou Y, Lei T, Wei D, Zhao Y (2023) Multiple roles of the stress sensor GCN2 in immune cells. Int J Mol Sci 24(5):4285","journal-title":"Int J Mol Sci"},{"key":"5395_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Ni Y, Liang X, Lin Y, An B, He X, Zhao X (2022) Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol 13:915094","journal-title":"Front Immunol"},{"issue":"1","key":"5395_CR121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Shen G, Zhou X, Li J (2025) Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther 10(1):178","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5395_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01407-1","volume":"23","author":"L Zhu","year":"2023","unstructured":"Zhu L, Wang J, Hu J (2023) High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer. BMC Endocr Disord 23(1):148","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"5395_CR123","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-024-07350-6","volume":"207","author":"X Zhuo","year":"2024","unstructured":"Zhuo X, Deng H, Qiu M, Qiu X (2024) Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis. Breast Cancer Res Treat 207(1):151\u2013165","journal-title":"Breast Cancer Res Treat"},{"key":"5395_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117320","volume":"14","author":"AE Ziegler","year":"2023","unstructured":"Ziegler AE, Fittje P, M\u00fcller LM, Ahrenstorf AE, Hagemann K, Hagen SH, Hess LU, Niehrs A, Poch T, Ravichandran G (2023) The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56bright NK cells. Front Immunol 14:1117320","journal-title":"Front Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05395-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:02:23Z","timestamp":1784779343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":124,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5395"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05395-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}